Literature DB >> 20096391

Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIX adjuvanted recombinant antigens.

Ana Vujanic1, Janet L K Wee, Kenneth J Snibson, Stirling Edwards, Martin Pearse, Charles Quinn, Margaret Moloney, Shirley Taylor, Jean-Pierre Y Scheerlinck, Philip Sutton.   

Abstract

Deep pulmonary delivery of an influenza ISCOMATRIX vaccine has previously been shown to induce a combined mucosal and systemic antibody response. To explore whether this combined response is influenced by intrinsic properties of the component antigen, we examined the efficacy of deep pulmonary delivery of ISCOMATRIX vaccines containing different recombinant antigens, specifically gB glycoprotein from cytomegalovirus and a fragment of catalase from Helicobacter pylori. Both these vaccines induced antigen-specific mucosal and systemic immunity, as well as antigen-specific proliferative cellular responses. Pulmonary immunisation with ISCOMATRIX vaccines may therefore be a generic way of inducing combined systemic and mucosal immunity. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096391     DOI: 10.1016/j.vaccine.2010.01.018

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Long-term antibody and immune memory response induced by pulmonary delivery of the influenza Iscomatrix vaccine.

Authors:  Ana Vujanic; Kenneth J Snibson; Janet L K Wee; Stirling J Edwards; Martin J Pearse; Jean-Pierre Y Scheerlinck; Philip Sutton
Journal:  Clin Vaccine Immunol       Date:  2011-11-09

2.  Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination.

Authors:  Chiara Nembrini; Armando Stano; Karen Y Dane; Marie Ballester; André J van der Vlies; Benjamin J Marsland; Melody A Swartz; Jeffrey A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

3.  ISCOMATRIX™ adjuvant reduces mucosal tolerance for effective pulmonary vaccination against influenza.

Authors:  Andrea A Timothy; Ana Tokanovic; Kenneth J Snibson; Stirling J Edwards; Martin J Pearse; Jean-Pierre Y Scheerlinck; Philip Sutton
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Microneedle and mucosal delivery of influenza vaccines.

Authors:  Sang-Moo Kang; Jae-Min Song; Yeu-Chun Kim
Journal:  Expert Rev Vaccines       Date:  2012-05       Impact factor: 5.217

5.  Controlling influenza by cytotoxic T-cells: calling for help from destroyers.

Authors:  Michael Schotsaert; Lorena Itatí Ibañez; Walter Fiers; Xavier Saelens
Journal:  J Biomed Biotechnol       Date:  2010-05-24

6.  An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines.

Authors:  Aiala Salvador; Manoli Igartua; Rosa Maria Hernández; José Luis Pedraz
Journal:  J Drug Deliv       Date:  2011-06-15

Review 7.  Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.

Authors:  Blaise Corthésy; Gilles Bioley
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

8.  Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100.

Authors:  Heng Liu; Harshad P Patil; Jacqueline de Vries-Idema; Jan Wilschut; Anke Huckriede
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.